WO1994012219A3 - Modified insulin-like growth factors - Google Patents
Modified insulin-like growth factors Download PDFInfo
- Publication number
- WO1994012219A3 WO1994012219A3 PCT/US1993/011458 US9311458W WO9412219A3 WO 1994012219 A3 WO1994012219 A3 WO 1994012219A3 US 9311458 W US9311458 W US 9311458W WO 9412219 A3 WO9412219 A3 WO 9412219A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- igf
- modified forms
- growth factors
- muteins
- peg
- Prior art date
Links
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title abstract 6
- 102000013275 Somatomedins Human genes 0.000 title abstract 6
- 229920001223 polyethylene glycol Polymers 0.000 abstract 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6513381A JPH08506095A (en) | 1992-11-25 | 1993-11-24 | Modified insulin-like growth factor |
AU60482/94A AU6048294A (en) | 1992-11-25 | 1993-11-24 | Modified insulin-like growth factors |
EP94907044A EP0679095A1 (en) | 1992-11-25 | 1993-11-24 | Modified insulin-like growth factors |
KR1019950702108A KR950703999A (en) | 1992-11-25 | 1993-11-24 | MODIFIED INSULIN-LIKE GROWTH FACTORS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98051992A | 1992-11-25 | 1992-11-25 | |
US07/980,519 | 1992-11-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1994012219A2 WO1994012219A2 (en) | 1994-06-09 |
WO1994012219A3 true WO1994012219A3 (en) | 1994-07-21 |
Family
ID=25527621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/011458 WO1994012219A2 (en) | 1992-11-25 | 1993-11-24 | Modified insulin-like growth factors |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0679095A1 (en) |
JP (1) | JPH08506095A (en) |
KR (1) | KR950703999A (en) |
AU (1) | AU6048294A (en) |
CA (1) | CA2149048A1 (en) |
WO (1) | WO1994012219A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8859497B2 (en) | 1997-07-14 | 2014-10-14 | Bolder Biotechnology, Inc. | Method of treatment using cysteine mutants of beta interferon |
US8957023B2 (en) | 1999-01-14 | 2015-02-17 | Bolder Biotechnology Inc. | Methods for making proteins containing free cysteine residues |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
WO1995032003A1 (en) * | 1994-05-24 | 1995-11-30 | Amgen Boulder Inc. | Modified insulin-like growth factors |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US6870033B1 (en) | 1997-02-21 | 2005-03-22 | Genentech, Inc. | Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies |
US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US7270809B2 (en) | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
BR9812267B1 (en) | 1997-07-14 | 2013-11-26 | Recombinant Growth Hormone. | |
US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
US7153943B2 (en) | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US6468532B1 (en) | 1998-01-22 | 2002-10-22 | Genentech, Inc. | Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates |
US6458355B1 (en) | 1998-01-22 | 2002-10-01 | Genentech, Inc. | Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates |
US7005504B2 (en) | 1998-01-22 | 2006-02-28 | Genentech, Inc. | Antibody fragment-peg conjugates |
JP2002510646A (en) | 1998-04-03 | 2002-04-09 | カイロン コーポレイション | Use of IGFI for treating articular cartilage disorders |
EP1144613B2 (en) * | 1999-01-14 | 2020-05-06 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
JP4670150B2 (en) | 1999-04-02 | 2011-04-13 | 味の素株式会社 | Method for producing subunit peptides derived from multimeric proteins |
US6309633B1 (en) * | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
JP4873818B2 (en) * | 2000-05-16 | 2012-02-08 | ボルダー バイオテクノロジー, インコーポレイテッド | Methods for refolding proteins containing free cysteine residues |
US20040186051A1 (en) | 2001-10-02 | 2004-09-23 | Kelley Robert F | Apo-2 ligand variants and uses thereof |
CA2489348A1 (en) | 2002-06-24 | 2003-12-31 | Genentech, Inc. | Apo-2 ligand/trail variants and uses thereof |
US20060228331A1 (en) | 2003-10-10 | 2006-10-12 | Novo Nordisk A/S | IL-21 Derivatives and variants |
EP1674113A1 (en) * | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
EP1893632B1 (en) * | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
WO2007041614A2 (en) | 2005-10-03 | 2007-04-12 | Bolder Biotechnology, Inc. | Long acting vegf inhibitors and methods of use |
WO2008025527A1 (en) | 2006-08-31 | 2008-03-06 | F. Hoffmann-La Roche Ag | Method for the production of insulin-like growth factor-i |
CL2007002502A1 (en) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | VARIANTS OF THE SIMILAR GROWTH FACTOR TO HUMAN INSULIN-1 (IGF-1) PEGILATED IN LISIN; METHOD OF PRODUCTION; FUSION PROTEIN THAT UNDERSTANDS IT; AND ITS USE TO TREAT ALZHEIMER'S DISEASE. |
US8475784B2 (en) | 2006-10-26 | 2013-07-02 | Novo Nordisk A/S | IL-21 variants |
EP2102355B1 (en) | 2006-12-14 | 2016-03-02 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
KR101485646B1 (en) * | 2010-02-11 | 2015-01-22 | 에프. 호프만-라 로슈 아게 | IGF-Ⅰ poly (ethylene glycol) conjugates |
CR20160132A (en) | 2013-08-12 | 2016-08-25 | Genentech Inc | COMPOSITIONS AND METHOD TO TREAT CONDITIONS ASSOCIATED WITH THE COMPLEMENT |
CA2944712A1 (en) | 2014-05-01 | 2015-11-05 | Genentech, Inc. | Anti-factor d antibody variants and uses thereof |
CN108472382A (en) | 2015-10-30 | 2018-08-31 | 豪夫迈·罗氏有限公司 | Anti- factor D antibody variants conjugate and application thereof |
JP2018534930A (en) | 2015-10-30 | 2018-11-29 | ジェネンテック, インコーポレイテッド | Anti-factor D antibodies and conjugates |
CA3169967A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Tie2-binding agents and methods of use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0458064A2 (en) * | 1990-05-04 | 1991-11-27 | American Cyanamid Company | Stabilization of somatotropins and other proteins by modification of cysteine residues |
US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
-
1993
- 1993-11-24 AU AU60482/94A patent/AU6048294A/en not_active Abandoned
- 1993-11-24 EP EP94907044A patent/EP0679095A1/en not_active Withdrawn
- 1993-11-24 CA CA002149048A patent/CA2149048A1/en not_active Abandoned
- 1993-11-24 JP JP6513381A patent/JPH08506095A/en active Pending
- 1993-11-24 KR KR1019950702108A patent/KR950703999A/en not_active Application Discontinuation
- 1993-11-24 WO PCT/US1993/011458 patent/WO1994012219A2/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
EP0458064A2 (en) * | 1990-05-04 | 1991-11-27 | American Cyanamid Company | Stabilization of somatotropins and other proteins by modification of cysteine residues |
Non-Patent Citations (2)
Title |
---|
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; * |
GLASS J D ET AL: "4-PHENOXY-3,5-DINITROBENZOYL POLYETHYLENE GLYCOL REVERSIBLE ATTACHMENT OF CYSTEINE CONTAINING POLYPEPTIDES TO POLYMERS IN AQUEOUS SOLUTIONS.", BIOPOLYMERS, vol. 18, no. 2, 1979, pages 383 - 392 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8859497B2 (en) | 1997-07-14 | 2014-10-14 | Bolder Biotechnology, Inc. | Method of treatment using cysteine mutants of beta interferon |
US8957023B2 (en) | 1999-01-14 | 2015-02-17 | Bolder Biotechnology Inc. | Methods for making proteins containing free cysteine residues |
Also Published As
Publication number | Publication date |
---|---|
EP0679095A1 (en) | 1995-11-02 |
AU6048294A (en) | 1994-06-22 |
JPH08506095A (en) | 1996-07-02 |
WO1994012219A2 (en) | 1994-06-09 |
CA2149048A1 (en) | 1994-06-09 |
KR950703999A (en) | 1995-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994012219A3 (en) | Modified insulin-like growth factors | |
AU2059088A (en) | A device for the administration of implants | |
IL104325A (en) | Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above | |
HUP0100507A2 (en) | Polyethylene glycol-grf conjugates, site-specific preparation thereof, pharmaceutical compositions comprising thereof and their use | |
MY125556A (en) | Aqueous formulations of peptide | |
KR970706842A (en) | Acylated Insulin Analogs | |
MD960288A (en) | Method for separating DNase forms , human DNase, pharmaceutical composition, DNase storage method, treatment method | |
HK1024865A1 (en) | Pharmaceutical compositions comprising a mixture of autocross-linked hyaluronic acid and nonautocross-linked hyaluronic acid and their use for the treatment of arthropathies | |
IL152659A (en) | Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer | |
GEP20022788B (en) | Pharmaceutical Compositions Having Appetite Suppressant Activity | |
DE60012557D1 (en) | COMPOSITIONS CONTAINING HYALURONIC ACID FOR THE DELIVERY OF OSTEOGENIC PROTEINS | |
EP1025840A3 (en) | Oral drug compositions and methods | |
ATE79763T1 (en) | USE OF AT LEAST ONE CYTOKINE IN THE MANUFACTURE OF A MEDICATION FOR THE SYSTEMIC TREATMENT OF PRAENEOPLASTIC LESIONS. | |
HK1048058A1 (en) | Hepatoselective pharmaceutical actives | |
ATE399567T1 (en) | PEG CONJUGATES OF LHRH ANALOGUE | |
MY135057A (en) | Dolastatin 15 derivatives | |
IE882091L (en) | Pharmaceutical compositions comprising sometostatin¹analogues | |
WO2002055532A3 (en) | Variant growth hormone molecules conjugated with macromolecular compounds | |
AR019066A1 (en) | HELIOMYCIN, NUCLEIC ACID FRAGMENTS CODING FOR HELIOMYCIN AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | |
IL104580A (en) | Parathormone fragments process for the preparation for the preparation thereof and pharmaceutical compositions containing them | |
EP0286441A3 (en) | Novel cytotoxic protein | |
WO2002058589A3 (en) | Agents and methods for promoting bone growth | |
WO2002081507A3 (en) | Interferon gamma polypeptide variants | |
DE69816808D1 (en) | SOMATOSTATIN AGONISTE FOR REDUCING BODY WEIGHT | |
WO1994016723A3 (en) | Wound healing composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
EX32 | Extension under rule 32 effected after completion of technical preparation for international publication | ||
LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2149048 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994907044 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1994907044 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1995 448514 Country of ref document: US Date of ref document: 19951204 Kind code of ref document: A |
|
EX32 | Extension under rule 32 effected after completion of technical preparation for international publication |
Free format text: AM+,KG+,MD+,TJ+,TM+ |
|
LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) |
Free format text: AM*,KG*,MD*,TJ*,TM* |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994907044 Country of ref document: EP |